Cancer Drug Design and Discovery
1st Edition
Secure Checkout
Personal information is secured with SSL technology.Free Shipping
Free global shippingNo minimum order.
Description
The ultimate source of information on the design of new anticancer agents, emphasizing small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumors. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing to a broad audience, this is an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry and clinicians taking oncology options.
Key Features
- Covers both currently available drugs as well as those under development
- Provides a clinical perspective on trials of new anticancer agents
- Presents drug discovery examples through the use of case histories
Readership
Translational researchers interested in cancer biology and medicine. Students in pharmacy, pharmacology, or medicinal and biological chemistry, as well as clinicians taking oncology options.
Table of Contents
Section I. Basic Principles
- Modern cancer drug discovery: Integrating targets, technologies and treatments
- Preclinical pharmacology and in vivo models
- Clinical trial designs for more rapid proof-of-principle and approval
Section II. Methodology - Structural biology and anticancer drug design
- Natural product chemistry and cancer drug discovery
- Pharmacokinetics & ADME optimization in drug discovery
Section III. Drugs in the clinic and laboratory - Temozolomide: from cytotoxic to molecularly-targeted agent
- Camptothecins for drug design, cancer cell death and gene targeting
- Targeting thymidylate synthase by antifolate drugs for the treatment of cancer
Section IV. New Agents - Targeting inactive kinases: structure as a foundation for cancer drug discovery
- Cell cycle inhibitors in cancer: current status and future directions
- Inhibition of DNA repair as a therapeutic target
- Heat shock protein-90 inhibitors: targeting the cancer chaperone for combinatorial blockade of oncogenic pathways
- Heat shock protein-90-directed therapeutics and target validation
- Inhibitors of tumour angiogenesis
- The biology and oncology of RAF–ERK signalling P53 as a therapeutic target
Section V. The reality of cancer drugs in the clinic - Cancer drug resistance
- Failure Modes in Anticancer Drug Discovery and Development
Details
- No. of pages:
- 496
- Language:
- English
- Copyright:
- © Academic Press 2008
- Published:
- 14th November 2007
- Imprint:
- Academic Press
- Hardcover ISBN:
- 9780123694485
- eBook ISBN:
- 9780080554952
About the Editors

Stephen Neidle
Stephen Neidle, DSc, PhD, ARCS, FRSC, Director of Cancer Research UK Biomolecular Structure Group, Director of the Centre for Cancer Medicines, Professor of Chemical Biology, The School of Pharmacy, University College London, UK
Affiliations and Expertise
The School of Pharmacy, University College London, UK

Stephen Neidle
Stephen Neidle, DSc, PhD, ARCS, FRSC, Director of Cancer Research UK Biomolecular Structure Group, Director of the Centre for Cancer Medicines, Professor of Chemical Biology, The School of Pharmacy, University College London, UK
Affiliations and Expertise
The School of Pharmacy, University College London, UK
Ratings and Reviews
Request Quote
Tax Exemption
Elsevier.com visitor survey
We are always looking for ways to improve customer experience on Elsevier.com.
We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit.
If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website.
Thanks in advance for your time.